Decision-Making Analysis for Selection of Antibiotic Treatment in Intra-Abdominal Infection Using Preference Measurements
- 1 October 2006
- journal article
- research article
- Published by Mary Ann Liebert Inc in Surgical Infections
- Vol. 7 (5), 453-462
- https://doi.org/10.1089/sur.2006.7.453
Abstract
Background: Antimicrobial therapy of abdominal infections is important to the prognosis of affected patients. The choice of antimicrobial therapy must consider effectiveness, safety, cost, and antibiotic resistance, among numerous factors. However, in reality, decisions are made assuming bioequivalence between regimens, without considering the specific attributes of any particular regimen. The objective was to determine the best antibiotic regimen for patients with community-acquired abdominal infection on the basis of a decision analysis that included effectiveness as well as safety, measured as adverse effects. Methods: A decision tree was built using information from a systematic review of the literature on the effectiveness of antimicrobial regimens tested in randomized clinical trials (RCTs) and the frequency and severity of adverse effects. The quality of the articles was assessed with the Oxford criteria for RCTs. The main outcome was preferences reported by surgeons, measured on a numeric scale. Preferences were obtained using a standard survey that reported each adverse effect with its respective intensity, reversibility, sequelae, duration of symptoms, and necessity for change of antibiotic. Each of the surgeons had to assign a value blindly from 0 to 10, where 10 was the most severe. A sensitivity analysis was conducted varying the frequency of adverse effects. Results: The regimens analyzed were amikacin-metronidazole, amikacin-clindamycin, ciprofloxacin-metronidazole, ampicillin-sulbactam, ceftriaxone-metronidazole, piperacillintazobactam, and ertapenem. The perceived severity of adverse effects reported were: Acute neuromuscular blockade (8.0), severe allergic reaction (7.5), ototoxicity (7.4), nephrotoxicity (7.1), antibiotic-associated colitis (7.0), peripheral neuropathy (5.3), general neurological symptoms (4.9), gastrointestinal symptoms (3.1), and other general symptoms (2.6). Favored regimens were ceftriaxone-metronidazole (1.15), ampicillin-sulbactam (1.24), piperacillin-tazobactam (1.27) and ertapenem (1.28). These strategies dominated the other therapeutic schemes. Sensitivity analysis showed no changes in the dominance reported when the frequency of adverse effects was maintained in the known clinical range. Conclusions: Antibiotic regimens that contain aminoglycosides are not bioequivalent to those without aminoglycosides when effectiveness and adverse effects are considered simultaneously. Antibiotic regimens that do not use aminoglycosides must be the first line of treatment for abdominal sepsis acquired in the community.Keywords
This publication has 59 references indexed in Scilit:
- A Prospective Observational Study of the Effect of Penicillin Skin Testing on Antibiotic Use in the Intensive Care UnitInfection Control & Hospital Epidemiology, 2003
- Hepatic biotransformation of the new calcium-mimetic agent, RWJ-68025, in the rat and in man — API-MS/MS identification of metabolitesJournal of Pharmacy and Pharmacology, 2003
- Aminoglycosides for Intra-Abdominal Infection: Equal to the Challenge?Surgical Infections, 2002
- Piperacillin/Tazobactam Compared with Cefuroxime/ Metronidazole in the Treatment of Intra-abdominal InfectionsThe European Journal of Surgery, 1999
- Results of a Randomized, Multicenter Trial of Meropenem Versus Clindamycin/Tobramycin for the Treatment of Intra-Abdominal InfectionsClinical Infectious Diseases, 1997
- Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infectionsInfection, 1995
- Incidence of and Significant Risk Factors for Aminoglycoside-Associated Nephrotoxicity in Patients Dosed by Using Individualized Pharmacokinetic MonitoringThe Journal of Infectious Diseases, 1993
- Nephrotoxicity and Ototoxicity of Aztreonam versus Aminoglycoside Therapy in Seriously III Nonneutropenic PatientsThe Journal of Infectious Diseases, 1992
- Comparison of Aztreonam plus Clindamycin with Tobramycin plus Clindamycin in the Treatment of Intra-Abdominal InfectionsChemotherapy, 1989